01:01 PM EST - Oncolytics Biotech Inc. : Announced that Thomas (Tom) C. Heineman , M.D., Ph.D., has been promoted to the role of Chief Medical Officer (CMO). Dr. Heineman has over two decades of experience leading clinical development programs and previously served as Oncolytics' Global Head of Clinical Development and Operations. “Tom's clinical expertise, deep understanding of oncology drug development, and impressive track record make him an ideal fit as our CMO," said Dr. Matt Coffey , President and Chief Executive Officer of Oncolytics Biotech Inc. "Since joining Oncolytics in August 2020 , Tom has provided crucial insights that have enabled the efficient advancement of our lead breast cancer program and facilitated our pipeline's expansion into additional indications. Looking forward, Tom's strategic guidance will continue to be an invaluable asset as we move towards a registration study in metastatic breast cancer and advance our broader pipeline." Oncolytics Biotech Inc.
shares T.ONC are trading up 7 cents at $2.00.
